Handbook of Drug Interactions

184 Mozayani and Mozayani
50. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors, 1st ed. Caddo,
OK: Professional Communications Inc., 1996.
51. Spina E, Avenoso A, Facciol G, Scordo M, Anciono M, and Madia A. Plasma concentrations
of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.
Ther Drug Monit 23(3):223–227 (2001).
52. Bostwick J and Brown T. A toxic reaction from combining fluoxetine and phentermine.
J Clin Psychopharmacol 16(2):189–190 (1996).
53. Mamiya K, Kojima K, Yukawa E, Higuchi S, Ieiri I, Ninomiya H, and Tashiro N. Phenytoin
intoxication induced by fluvoxamine. Ther Drug Monit 23(1):75–77 (2001).
54. Eap C, Bertschy G, Powell K, and Baumann P. Fluvoxamine and fluoxetine do not interact
in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol
17(2):113–117 (1997).
55. Preskorn S, Greenblatt D, and Harvey A. Lack of effect of sertraline on the pharmacokinetics
of alprazolam. J Clin Psychopharmacol 20(5):585–586 (2000).
56. Taylor D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination.
Interactions and therapeutic uses. Br J Psychiatry 167(5):575–580 (1995).
57. Markowitz J and DeVane CL. Rifampin induced selective serotonin reuptake inhibitor withdrawal
syndrome in a patient treated with sertraline. J Clin Psychopharmacol 20(1):109–110
(2000).
58. Hemeryck A, De Vriendt C, and Belapaire FM. Effect of selective serotonin reuptake inhibitors
on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes.
J Clin Psychopharmacol 20(4):428–434 (2000).
59. Sayal K, Duncan-McConnell DA, McConnell HW, and Taylor D. Psychotropic interactions
with warfarin. Acta Psychiatr Scand 102(4):250–255 (2000).
60. Nelson MH, Birnbauma AK, and Remmel RP. Inhibition of phenytoin hydroxylation in
human liver microsomes by several selective serotonin reuptake inhibitors. Epilepsy Res
44(1):71–82 (2001).
61. Moller SE, Larsen F, Khan A, and Rolan PE. Lack of effect of citalopram on the steady
state pharmacokinetics of carbamazepine in healthy male subjects. J Clin Psychopharmacol
21(5):493–499 (2001).
62. Bertschy G, Eap CB, Powell K, and Baumann P. Fluoxetine addition to methadone in
addicts: pharmacokinetic aspects. Ther Drug Monit 18(5):570–572 (1996).
63. Bauer M, Zaninelli R, Muller-Oerlinghausen B, and Meister W. Paroxetine and amitriptyline
augmentation of lithium in the treatment of major depression: a double-blind study.
J Clin Psychopharmacol 19(2):164–171 (1999).
64. Fagiolini A, Buysse DJ, Frank E, Houck P, Luther JF, and Kupfer DJ. Tolerability of combined
treatment with lithium and paroxetine in patients with bipolar disorder and depression.
J Clin Psychopharmacol 21(5):474–478 (2001).
65. Hemeryck A, Lefebvre R, De Vriendt CE, and Belpaire FM. Paroxetine affects metoprolol
pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 67(3):
283–291 (2000).
66. Hassan P, Sproule B, Naranjo C, and Hermann N. Dose-response evaluation of the interaction
between sertraline and alprazolam in vivo. J Clin Psychopharmacol 20(2):150–158
(2000).
67. Scott GN and Elmer GW. Update on natural product-drug interactions. Am J Health Syst
Pharm 59(4):339–347 (2002).
68. Callaway JC and Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a
potential combination for severe adverse interactions. J Psychoactive Drugs 30(4):367–369
(1998).